Next Article in Journal
Formulation Considerations for the Management of Dry Eye Disease
Next Article in Special Issue
Sulfated Lactosyl Archaeol Archaeosomes Synergize with Poly(I:C) to Enhance the Immunogenicity and Efficacy of a Synthetic Long Peptide-Based Vaccine in a Melanoma Tumor Model
Previous Article in Journal
The Synergistic Effects of Sulfated Lactosyl Archaeol Archaeosomes When Combined with Different Adjuvants in a Murine Model
Previous Article in Special Issue
Cyclic Di-Adenosine Monophosphate: A Promising Adjuvant Candidate for the Development of Neonatal Vaccines
Review

Lipid Nanoparticles as Delivery Systems for RNA-Based Vaccines

Department of Pharmaceutics, College of Pharmacy, King Saud University, Riyadh 11495, Saudi Arabia
*
Author to whom correspondence should be addressed.
Academic Editor: Wouter L. J. Hinrichs
Pharmaceutics 2021, 13(2), 206; https://doi.org/10.3390/pharmaceutics13020206
Received: 28 November 2020 / Revised: 27 January 2021 / Accepted: 28 January 2021 / Published: 2 February 2021
(This article belongs to the Special Issue Discovery and Evaluation of Novel Adjuvants for Vaccine Formulations)
There has been increased interest in the development of RNA-based vaccines for protection against various infectious diseases and also for cancer immunotherapies. Rapid and cost-effective manufacturing methods in addition to potent immune responses observed in preclinical and clinical studies have made mRNA-based vaccines promising alternatives to conventional vaccine technologies. However, efficient delivery of these vaccines requires that the mRNA be protected against extracellular degradation. Lipid nanoparticles (LNPs) have been extensively studied as non-viral vectors for the delivery of mRNA to target cells because of their relatively easy and scalable manufacturing processes. This review highlights key advances in the development of LNPs and reviews the application of mRNA-based vaccines formulated in LNPs for use against infectious diseases and cancer. View Full-Text
Keywords: lipid nanoparticles; cationic lipids; vaccines; cancer immunotherapy; mRNA; nucleic acid; adjuvant; delivery system; nanotechnology lipid nanoparticles; cationic lipids; vaccines; cancer immunotherapy; mRNA; nucleic acid; adjuvant; delivery system; nanotechnology
Show Figures

Figure 1

MDPI and ACS Style

Aldosari, B.N.; Alfagih, I.M.; Almurshedi, A.S. Lipid Nanoparticles as Delivery Systems for RNA-Based Vaccines. Pharmaceutics 2021, 13, 206. https://doi.org/10.3390/pharmaceutics13020206

AMA Style

Aldosari BN, Alfagih IM, Almurshedi AS. Lipid Nanoparticles as Delivery Systems for RNA-Based Vaccines. Pharmaceutics. 2021; 13(2):206. https://doi.org/10.3390/pharmaceutics13020206

Chicago/Turabian Style

Aldosari, Basmah N., Iman M. Alfagih, and Alanood S. Almurshedi 2021. "Lipid Nanoparticles as Delivery Systems for RNA-Based Vaccines" Pharmaceutics 13, no. 2: 206. https://doi.org/10.3390/pharmaceutics13020206

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop